Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner
Collectively, these studies illustrate that HO1 may act as a successful treatment target for gilteritinib-resistant FLT3-ITD AML patients.
Authors
- Zhengmei Long
- Min Liu (ORCID: https://orcid.org/0000-0003-1298-4441)
- Qian Kang (ORCID: https://orcid.org/0000-0001-5825-1660)
- Tianzhuo Zhang
- Xueying Yang (ORCID: https://orcid.org/0009-0001-9777-7902)
- Danna Wei (ORCID: https://orcid.org/0000-0003-0966-1289)
- Peng Zhao (ORCID: https://orcid.org/0000-0001-6216-3858)
- Rui Gao (ORCID: https://orcid.org/0000-0002-4704-206X)
- Jishi Wang (ORCID: https://orcid.org/0000-0002-0547-2360)
- Tingting Lu (ORCID: https://orcid.org/0000-0001-6998-5969)
- Luxin Zhang (ORCID: https://orcid.org/0000-0002-3121-0364)
- Yun Zhan
Institutions
- Guiyang Medical University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1186/s12935-025-03757-3
- Citations
- 4
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 7.08
Funders
- National Natural Science Foundation of China